Roivant Sciences Ltd. filed a Form 8-K current report on September 8, 2026, disclosing positive results from the PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease.
Key Highlights
- Positive trial results: Roivant Sciences announced positive results from the PHocus clinical trial evaluating mosliciguat.
- Target indication: Mosliciguat is being evaluated for pulmonary hypertension associated with interstitial lung disease.
- Subsidiary conducting trial: The PHocus trial is conducted by Roivant's subsidiary, Pulmovant, Inc.
- Disclosure method: Results were announced via a press release dated September 8, 2026, attached as Exhibit 99.1.
- Listing: Roivant Sciences Common Shares trade on The Nasdaq Global Select Market under the symbol ROIV.
PHocus Trial Disclosure: Mosliciguat for Pulmonary Hypertension in ILD
According to the filing, Roivant Sciences Ltd. (NASDAQ:ROIV) issued a press release on September 8, 2026, announcing what it described as "positive results" from the PHocus clinical trial. The trial evaluates mosliciguat as a treatment for pulmonary hypertension associated with interstitial lung disease, a condition abbreviated in the filing's context as PH-ILD. The trial is being conducted by Pulmovant, Inc., identified in the filing as a subsidiary of Roivant Sciences.
The disclosure was made under Item 7.01 of the Form 8-K, which covers Regulation FD disclosures. The filing explicitly noted that the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933." The full press release containing the trial results was attached as Exhibit 99.1 and incorporated by reference into the current report.
The filing was signed by Keyur Parekh in the capacity of Authorized Signatory on behalf of Roivant Sciences Ltd., a Bermuda-incorporated company with principal executive offices located at 7th Floor, 50 Broadway, London, SW1H 0DB, United Kingdom. No additional financial data, specific trial endpoints, or numerical clinical outcomes were included within the body of the 8-K itself; those details are contained in the attached press release.
What Was Disclosed
Roivant Sciences filed an 8-K on September 8, 2026, under Regulation FD, announcing positive PHocus clinical trial results for mosliciguat in pulmonary hypertension associated with interstitial lung disease, with the full press release attached as Exhibit 99.1.



Please wait processing your request...